CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Lineage Cell Therapeutics, Inc. - LCTX CFD

1.12
2.59%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Lineage Cell Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.16
Open* 1.15
1-Year Change* 1.77%
Day's Range* 1.13 - 1.17
52 wk Range 1.02-1.58
Average Volume (10 days) 310.50K
Average Volume (3 months) 15.99M
Market Cap 241.48M
P/E Ratio -100.00K
Shares Outstanding 174.99M
Revenue 10.52M
EPS -0.13
Dividend (Yield %) N/A
Beta 1.66
Next Earnings Date Nov 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 22, 2023 1.16 -0.07 -5.69% 1.23 1.24 1.16
Sep 21, 2023 1.23 -0.03 -2.38% 1.26 1.27 1.23
Sep 20, 2023 1.26 0.00 0.00% 1.26 1.28 1.26
Sep 19, 2023 1.28 0.01 0.79% 1.27 1.31 1.27
Sep 18, 2023 1.29 -0.01 -0.77% 1.30 1.32 1.28
Sep 15, 2023 1.30 0.03 2.36% 1.27 1.33 1.26
Sep 14, 2023 1.28 0.01 0.79% 1.27 1.30 1.26
Sep 13, 2023 1.28 -0.01 -0.78% 1.29 1.31 1.28
Sep 12, 2023 1.30 0.01 0.78% 1.29 1.32 1.28
Sep 11, 2023 1.29 0.01 0.78% 1.28 1.34 1.28
Sep 8, 2023 1.33 0.00 0.00% 1.33 1.37 1.33
Sep 7, 2023 1.35 0.04 3.05% 1.31 1.36 1.31
Sep 6, 2023 1.33 -0.03 -2.21% 1.36 1.36 1.32
Sep 5, 2023 1.34 0.02 1.52% 1.32 1.38 1.31
Sep 1, 2023 1.32 0.00 0.00% 1.32 1.34 1.30
Aug 31, 2023 1.29 -0.04 -3.01% 1.33 1.35 1.29
Aug 30, 2023 1.32 -0.01 -0.75% 1.33 1.39 1.32
Aug 29, 2023 1.35 0.04 3.05% 1.31 1.37 1.30
Aug 28, 2023 1.33 0.01 0.76% 1.32 1.35 1.32
Aug 25, 2023 1.32 -0.02 -1.49% 1.34 1.34 1.30

Lineage Cell Therapeutics, Inc. Events

Time (UTC) Country Event
Wednesday, November 8, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Lineage Cell Therapeutics Inc Earnings Release
Q3 2023 Lineage Cell Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Thursday, March 7, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Lineage Cell Therapeutics Inc Earnings Release
Q4 2023 Lineage Cell Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 14.703 4.341 1.826 3.515 4.988
Revenue 14.703 4.341 1.826 3.515 4.988
Cost of Revenue, Total 0.728 1.426 0.385 0.412 0.302
Gross Profit 13.975 2.915 1.441 3.103 4.686
Total Operating Expense 37.223 53.029 28.273 42.391 -31.728
Selling/General/Admin. Expenses, Total 22.508 18.212 15.571 24.031 24.726
Research & Development 13.887 33.714 11.117 15.948 18.755
Unusual Expense (Income) 0 -0.523 0 -77.711
Operating Income -22.52 -48.688 -26.447 -38.876 36.716
Interest Income (Expense), Net Non-Operating -1.365 3.727 1.817 16.499 -82.531
Other, Net -1.927 1.691 2.706 3.143 -1.315
Net Income Before Taxes -25.812 -43.27 -21.924 -19.234 -47.13
Net Income After Taxes -26.353 -43.27 -20.685 -11.827 -46.784
Minority Interest 0.08 0.251 0.036 0.118 0.794
Net Income Before Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
Net Income -26.273 -43.019 -20.649 -11.709 -45.99
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
Income Available to Common Incl. Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
Dilution Adjustment
Diluted Net Income -26.273 -43.019 -20.649 -11.709 -45.99
Diluted Weighted Average Shares 169.792 164.502 150.044 145.533 126.903
Diluted EPS Excluding Extraordinary Items -0.15474 -0.26151 -0.13762 -0.08046 -0.3624
Diluted Normalized EPS -0.15474 -0.26469 -0.13762 -0.08046 -0.75823
Depreciation / Amortization 0.1 0.2 1.2 2 2.2
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3.225 2.386 1.915 2.998 4.553
Revenue 3.225 2.386 1.915 2.998 4.553
Cost of Revenue, Total 0.127 0.119 0.102 0.235 0.215
Gross Profit 3.098 2.267 1.813 2.763 4.338
Total Operating Expense 8.249 9.028 8.554 8.249 8.787
Selling/General/Admin. Expenses, Total 4.249 4.724 4.348 4.422 5.27
Research & Development 3.873 4.185 4.104 3.592 3.302
Depreciation / Amortization
Operating Income -5.024 -6.642 -6.639 -5.251 -4.234
Interest Income (Expense), Net Non-Operating 0.232 0.45 -0.123 0.151 -0.658
Other, Net -0.411 -0.015 0.4 -0.475 -1.89
Net Income Before Taxes -5.203 -6.207 -6.362 -5.575 -6.782
Net Income After Taxes -5.203 -4.404 -6.362 -6.116 -6.782
Minority Interest -0.026 0.032 0.008 0.047 0.019
Net Income Before Extra. Items -5.229 -4.372 -6.354 -6.069 -6.763
Net Income -5.229 -4.372 -6.354 -6.069 -6.763
Income Available to Common Excl. Extra. Items -5.229 -4.372 -6.354 -6.069 -6.763
Income Available to Common Incl. Extra. Items -5.229 -4.372 -6.354 -6.069 -6.763
Diluted Net Income -5.229 -4.372 -6.354 -6.069 -6.763
Diluted Weighted Average Shares 170.592 170.127 170.002 169.786 169.731
Diluted EPS Excluding Extraordinary Items -0.03065 -0.0257 -0.03738 -0.03574 -0.03985
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.03065 -0.0257 -0.03738 -0.03574 -0.03985
Unusual Expense (Income) 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 60 111.549 43.999 57.519 36.358
Cash and Short Term Investments 57.875 58.358 41.562 30.716 30.741
Cash & Equivalents 11.355 55.742 32.585 9.497 23.587
Short Term Investments 46.52 2.616 8.977 21.219 7.154
Total Receivables, Net 0.297 50.84 0.004 23.94 3.719
Accounts Receivable - Trade, Net 0.297 50.84 0.004 0.044 0.891
Prepaid Expenses 1.828 2.351 2.433 2.863 1.898
Total Assets 123.664 174.545 107.949 125.478 101.66
Property/Plant/Equipment, Total - Net 5.673 4.872 5.63 8.175 5.835
Property/Plant/Equipment, Total - Gross 11.523 10.174 9.945 12.766 9.02
Accumulated Depreciation, Total -5.85 -5.302 -4.315 -4.591 -3.185
Intangibles, Net 46.692 46.822 47.032 48.248 3.125
Long Term Investments 0 33.733
Other Long Term Assets, Total 0.627 0.63 0.616 0.864 0.505
Total Current Liabilities 18.981 47.116 7.769 6.494 6.812
Accounts Payable 2.393 3.543 2.611 2.427 2.359
Accrued Expenses 7.131 25.049 4.416 3.985 4.332
Notes Payable/Short Term Debt 0 0 0.523 0 0
Current Port. of LT Debt/Capital Leases 0.036 0.03 0.016 0.033 0.07
Other Current Liabilities, Total 9.421 18.494 0.203 0.049 0.051
Total Liabilities 50.325 82.324 11.75 12.519 7.82
Total Long Term Debt 0.084 0.03 0.026 0.077 1.958
Long Term Debt 0
Capital Lease Obligations 0.084 0.03 0.026 0.077 1.958
Minority Interest -1.403 -1.323 -1.072 -1.712 -1.594
Other Liabilities, Total 30.587 34.425 2.951 4.345 0.644
Total Equity 73.339 92.221 96.199 112.959 93.84
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 440.28 434.529 393.944 387.062 354.27
Retained Earnings (Accumulated Deficit) -363.37 -337.097 -294.078 -273.422 -261.856
Treasury Stock - Common
Other Equity, Total -3.571 -5.211 -3.667 -0.681 1.426
Total Liabilities & Shareholders’ Equity 123.664 174.545 107.949 125.478 101.66
Total Common Shares Outstanding 170.093 169.477 153.096 149.804 127.136
Note Receivable - Long Term 0 22.104
Goodwill, Net 10.672 10.672 10.672 10.672
Deferred Income Tax 2.076 2.076 2.076 3.315
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 49.655 60 68.509 74.026 81.872
Cash and Short Term Investments 46.814 57.875 66.355 72.03 79.944
Cash & Equivalents 15.451 11.355 24.752 70.857 78.062
Short Term Investments 31.363 46.52 41.603 1.173 1.882
Total Receivables, Net 0.203 0.297 0.434 0.707 0.515
Accounts Receivable - Trade, Net 0.203 0.297 0.434 0.707 0.515
Prepaid Expenses 2.638 1.828 1.72 1.289 1.413
Total Assets 113.205 123.664 131.148 135.922 144.52
Property/Plant/Equipment, Total - Net 5.584 5.673 4.652 3.869 4.548
Property/Plant/Equipment, Total - Gross 11.694 11.523 10.464 9.414 10.135
Accumulated Depreciation, Total -6.11 -5.85 -5.812 -5.545 -5.587
Goodwill, Net 10.672 10.672 10.672 10.672 10.672
Intangibles, Net 46.659 46.692 46.724 46.757 46.789
Other Long Term Assets, Total 0.635 0.627 0.591 0.598 0.639
Total Current Liabilities 17.225 18.981 22.739 25.091 24.593
Accounts Payable 3.001 2.393 2.865 2.589 2.956
Accrued Expenses 3.126 7.131 7.46 6.678 6.642
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.051 0.036 0.025 0.029 0.031
Other Current Liabilities, Total 11.047 9.421 12.389 15.795 14.964
Total Liabilities 42.755 50.325 52.2 53.075 57.973
Total Long Term Debt 0.133 0.084 0.016 0.019 0.026
Capital Lease Obligations 0.133 0.084 0.016 0.019 0.026
Deferred Income Tax 0.273 2.076 2.076 2.076 2.076
Minority Interest -1.435 -1.403 -1.395 -1.348 -1.329
Other Liabilities, Total 26.559 30.587 28.764 27.237 32.607
Total Equity 70.45 73.339 78.948 82.847 86.547
Common Stock 441.299 440.28 439.148 437.151 435.818
Retained Earnings (Accumulated Deficit) -367.742 -363.37 -357.016 -350.947 -344.184
Other Equity, Total -3.107 -3.571 -3.184 -3.357 -5.087
Total Liabilities & Shareholders’ Equity 113.205 123.664 131.148 135.922 144.52
Total Common Shares Outstanding 170.174 170.093 169.886 169.748 169.727
Preferred Stock - Non Redeemable, Net 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -26.273 -43.019 -20.649 -11.709 -45.99
Cash From Operating Activities 1.059 -23.561 -19.753 -31.947 -30.882
Cash From Operating Activities 0.582 0.663 0.895 1.131 1.081
Amortization 0.145 0.21 1.216 1.998 2.192
Deferred Taxes
Non-Cash Items 7.901 -2.511 -2.516 -21.464 11.197
Cash Interest Paid 0.013 0.013 0.02 0.028 0.155
Changes in Working Capital 18.704 21.096 1.301 -1.903 0.638
Cash From Investing Activities -46.159 9.745 13.038 16.957 11.816
Capital Expenditures -0.413 -0.354 -0.064 -0.44 -3.287
Other Investing Cash Flow Items, Total -45.746 10.099 13.102 17.397 15.103
Cash From Financing Activities 1.632 36.93 29.865 0.617 5.774
Financing Cash Flow Items -0.123 -1.155 -0.383 0.654 0.161
Issuance (Retirement) of Stock, Net 1.787 38.105 5.127 0.063 5.962
Issuance (Retirement) of Debt, Net -0.032 -0.02 25.121 -0.1 -0.349
Foreign Exchange Effects -0.873 -0.02 -0.063 0.07 0.006
Net Change in Cash -44.341 23.094 23.087 -14.303 -13.286
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.372 -26.273 -19.919 -13.85 -7.087
Cash From Operating Activities -11.242 1.059 9.362 14.842 21.904
Cash From Operating Activities 0.138 0.582 0.441 0.296 0.15
Amortization 0.033 0.145 0.113 0.065 0.032
Non-Cash Items 1.098 7.901 7.168 5.861 1.685
Cash Interest Paid 0.002 0.013 0.013 0.009 0.005
Changes in Working Capital -8.139 18.704 21.559 22.47 27.124
Cash From Investing Activities 15.426 -46.159 -41.057 -0.143 -0.046
Capital Expenditures -0.188 -0.413 -0.429 -0.143 -0.046
Other Investing Cash Flow Items, Total 15.614 -45.746 -40.628 0 0
Cash From Financing Activities 0.001 1.632 1.51 0.546 0.513
Financing Cash Flow Items -0.037 -0.123 -0.112 -0.074 -0.008
Issuance (Retirement) of Stock, Net 0.051 1.787 1.645 0.635 0.529
Foreign Exchange Effects -0.1 -0.873 -0.795 -0.161 -0.042
Net Change in Cash 4.085 -44.341 -30.98 15.084 22.329
Deferred Taxes 0 0
Issuance (Retirement) of Debt, Net -0.013 -0.032 -0.023 -0.015 -0.008
Cash Taxes Paid 1.803

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lineage Cell Therapeutics, Inc. Company profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company''s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Industry: Biotechnology & Medical Research (NEC)

2173 Salk Ave Ste 200
CARLSBAD
CALIFORNIA 92008-7354
US

Income Statement

  • Annual
  • Quarterly

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

US100

14,731.50 Price
+0.270% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.51 Price
-0.350% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

ETH/USD

1,594.77 Price
+0.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

BTC/USD

26,384.95 Price
-0.550% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading